Welcome to our dedicated page for Biomerica news (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on Biomerica stock.
Biomerica, Inc. (NASDAQ: BMRA) is a global biomedical technology company focused on advanced diagnostic and therapeutic products, with an emphasis on gastrointestinal and inflammatory diseases. The Biomerica news feed on Stock Titan highlights company announcements that explain how its diagnostic-guided therapies, rapid screening tests, and contract development and manufacturing (CDMO) services are evolving over time.
Readers can follow updates on the inFoods® IBS diagnostic-guided therapy, including clinical evidence, commercialization partnerships, and reimbursement milestones. Recent news has covered the American Medical Associations approval of a PLA code for inFoods IBS and the Centers for Medicare & Medicaid Services (CMS) decision to set a national Medicare payment rate for the test. Articles also describe the launch of the AI-backed inFoods IBS Trigger Food Navigator, a digital companion tool designed to support personalized IBS dietary therapy.
Biomerica news also covers regulatory authorizations and international expansion for its rapid screening portfolio. Examples include authorization by the Egyptian Drug Authority for the companys complete screening test portfolio and approvals by the United Arab Emirates Ministry of Health and Prevention for the Fortel® Ulcer and Fortel® Kidney tests for home use. These items provide insight into how Biomericas products are being introduced into new markets and care settings.
Investors and healthcare observers can also track updates on Biomericas expanding CDMO services, board and governance changes, and periodic financial results that discuss revenue mix, cost discipline, and the shift toward higher-margin diagnostic-guided therapy products and services. Bookmark this page to monitor BMRA news related to product launches, clinical publications, regulatory developments, commercial partnerships, and strategic initiatives as disclosed by the company.
Biomerica (Nasdaq: BMRA) received its first commercial order for Hp Detect™, a stool antigen test for Helicobacter pylori, from one of Europe’s largest clinical laboratory chains. The initial order targets the United Kingdom, where Hp Detect™ gained MHRA registration in February 2026.
Company says the account is a strategic reference customer with potential for recurring orders and wider EU distribution as Hp Detect™ is integrated into routine testing workflows, supported by NHS UK guidance recommending H. pylori testing for dyspepsia patients.
Biomerica (Nasdaq: BMRA) received MHRA registration on March 5, 2026 for its hp+detect™ diagnostic test, authorizing commercial sales in Great Britain.
The test detects Helicobacter pylori; the company is in active discussions with UK partners to access diagnostic labs and will provide updates as agreements are finalized.
Biomerica (Nasdaq: BMRA) reported real-world responder results for inFoods® IBS: 59.4% of 69 patients had ≥30% abdominal pain reduction and 68.1% had ≥30% bloating reduction using the FDA-recognized responder endpoint.
Mean pain scores fell 34.6% and bloating 41.7% at 8 weeks. Commercial milestones include a $300 national Medicare rate (effective Jan 1, 2026), a dedicated CPT PLA code (effective Oct 1, 2025), and a Henry Schein marketing services agreement.
Biomerica (Nasdaq: BMRA) announced that Vietnam’s Hanoi Department of Health approved EZ Detect™ for nationwide sales and distribution on Feb 18, 2026. The FDA-cleared, two-minute at-home colorectal screening test will be sold via a major distributor across pharmacies, hospitals, clinics, and online channels.
The approval targets Vietnam’s high unmet need: 16,835 new colorectal cancer cases in 2022 and a reported 45% five-year survival rate, versus 91% when detected early in the US.
Biomerica (Nasdaq: BMRA) reported Q2 fiscal 2026 results for the period ended November 30, 2025. Q2 revenue was $1.21M versus $1.64M year-ago and six-month revenue was $2.59M versus $3.44M prior year. Management highlighted a strategic pivot to higher-margin diagnostic-guided therapy products and cost discipline. Working capital improved 14.7% (about $457k) and cash increased to $2.5M. CMS later established a $300 Medicare payment rate for inFoods IBS effective January 1, 2026. Operating expenses declined year-to-date and R&D spending was reduced by 27% as the company reallocates resources to commercialization.
Biomerica (Nasdaq: BMRA) announced that CMS set a national Medicare payment rate of $300 for the inFoods® IBS test under the CLFS, effective for services paid with dates of service on or after January 1, 2026. The test secured a dedicated CPT® PLA code effective October 1, 2025. Medicare represents roughly 21% of US healthcare spending and Medicare-age adults are a meaningful share of IBS patients, supporting potential access expansion.
Clinical data from a randomized, multicenter trial showed 59.6% response for trigger-food elimination versus 42.2% control; subgroup results included 67.1% (IBS-C) and 66% (IBS-M) meeting FDA pain-reduction targets.
Biomerica (Nasdaq: BMRA) announced on Dec 11, 2025 that the Egyptian Drug Authority authorized its complete portfolio of rapid screening tests for marketing and distribution in Egypt.
The authorization covers at‑home and point‑of‑care tests for colorectal disease, breast self exam, prostate (PSA), kidney (microalbumin) and H. pylori, offering results in minutes without lab processing to support mass screening and individual use across Egypt and the MENA region.
Biomerica (NASDAQ: BMRA) announced that its inFoods® IBS diagnostic-guided dietary therapy is featured in the Fall 2025 issue of Biotherapeutics Quarterly, highlighting results from a randomized, multicenter, double-blind, placebo-controlled trial.
The study enrolled 223 IBS patients across 8 U.S. academic centers and found 59.6% of treated patients met the FDA abdominal pain reduction target versus 42.1% for control. Subgroup results: IBS-C 67.1% vs 35.8%; IBS-M 66.0% vs 29.5%. The assay tests IgG responses to 18 IBS-specific foods and typically identifies elimination of 2–4 foods per patient, positioned as a more targeted alternative to broad diets like low-FODMAP.
Biomerica (Nasdaq: BMRA) announced an expansion of its Contract Development and Manufacturing Organization (CDMO) services on Nov 6, 2025 to meet rising demand from diagnostic and biotechnology companies.
The company highlighted end-to-end capabilities across LFA, point-of-care, ELISA, multiplex ELISA, antibody/reagent services, recombinant antibody development, manufacturing/assembly, and global supply chain & technology transfer. Biomerica cited ISO 13485, CE-mark expertise, and an FDA-registered cGMP facility and said CDMO work is a growing contributor to revenue.
Biomerica (NASDAQ: BMRA) announced on October 16, 2025 a marketing services agreement with Henry Schein (NASDAQ: HSIC) to market the inFoods® Irritable Bowel Syndrome (IBS) test across the U.S., excluding New York State. Henry Schein will leverage its nationwide network of >400 medical field sales and telesales representatives to promote the non‑drug, precision diagnostic therapy to primary care and gastroenterology practices.
A multicenter, double‑blinded study published in Gastroenterology (June 2025) showed statistically significant outcomes: 59.6% treatment vs 42.2% control for abdominal pain reduction overall; 67.1% vs 35.8% in IBS‑C; 66% vs 29.5% in IBS‑M. IBS affects an estimated 10–15% of U.S. adults.